The CD45+ immune cells were predominantly myeloid cells, with a significantly increased proportion of CD11b+F4/80+ expressing TAMs and CD11b+CD11c+MHCII+ expressing dendritic cells (DCs) in RT-treated tumours compared to control untreated tumours. This evidence concerns the gene PTPRC and neoplasm.